Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials
Open Access
- 11 July 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 31 (9) , 1425-1436
Abstract
Chronic kidney disease (CKD) is strongly associated with increased risks of progression to end-stage kidney disease (ESKD) and mortality. Clinical trials evaluating CKD progression commonly use a composite end point of death, ESKD or serum creatinine doubling. However, due to low event rates, such trials require large sample sizes and long-term follow-up for adequate statistical power. As a result, very few interventions targeting CKD progression have been tested in randomized controlled trials. To overcome this problem, the National Kidney Foundation and Food and Drug Administration conducted a series of analyses to determine whether an end point of 30 or 40% decline in estimated glomerular filtration rate (eGFR) over 2–3 years can substitute for serum creatinine doubling in the composite end point. These analyses demonstrated that these alternate kidney end points were significantly associated with subsequent risks of ESKD and death. However, the association between, and consistency of treatment effects on eGFR decline and clinical end points were influenced by baseline eGFR, follow-up duration and acute hemodynamic effects. The investigators concluded that a 40% eGFR decline is broadly acceptable as a kidney end point across a wide baseline eGFR range and that a 30% eGFR decline may be acceptable in some situations. Although these alternate kidney end points could potentially allow investigators to conduct shorter duration clinical trials with smaller sample sizes thereby generating evidence to guide clinical decision-making in a timely manner, it is uncertain whether these end points will improve trial efficiency and feasibility. This review critically appraises the evidence, strengths and limitations pertaining to eGFR end points.Keywords
This publication has 56 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseAnnals of Internal Medicine, 2012
- Biomarkers and surrogate endpoints in clinical trialsStatistics in Medicine, 2012
- Trial Quality in Nephrology: How Are We Measuring Up?American Journal of Kidney Diseases, 2011
- A Randomized, Controlled Trial of Early versus Late Initiation of DialysisNew England Journal of Medicine, 2010
- Comparison of the Prevalence and Mortality Risk of CKD in Australia Using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR Estimating Equations: The AusDiab (Australian Diabetes, Obesity and Lifestyle) StudyAmerican Journal of Kidney Diseases, 2010
- The impact of automated eGFR reporting and education on nephrology service referralsNephrology Dialysis Transplantation, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Use of Composite End Points to Measure Clinical Events2003
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997